Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma

doi:10.1155/2022/8767333

	Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma
	Liu, Xin 2; Fu, Meng 1,3,4; Xia, Daqing 1; Ji, Zimei 1; Hu, Nana 1; Leng, Zaijun 1; Xie, Wang 1; Fang, Yuan 1; Zhang, Junqiang 1,2
刊名	JOURNAL OF ONCOLOGY
	2022-10-05
卷号	2022
ISSN号	1687-8450
DOI	10.1155/2022/8767333
通讯作者	Zhang, Junqiang(yany1980@126.com)
英文摘要	Family with sequence similarity 83, member A (FAM83A) plays an essential and fundamental role in the proliferation, progression, and apoptosis of many malignant tumors, including lung cancer. This study aimed to determine the expression pattern of FAM83A in lung adenocarcinoma (LUAD) and its correlation with the prognosis of cancer and the survival of the patients. Bioinformatics analysis, immunohistochemistry, and Western blotting were used to explore and detect the expression of FAM83A in LUAD cells. The mechanism of FAM83A in proliferation and migration was examined. The correlation between FAM83A expression and survival rate was assessed by the Kaplan-Meier and Cox regression. FAM83A expression was elevated in LUAD tissues and was related to shorter overall survival (P < 0.05). A significant increase in FAM83A protein was observed in the LUAD tissue (P < 0.05). Compared with patients with early-stage tumors (stage I-II), those with advanced stage tumors (stage III-IV) had significantly higher FAM83A expression levels (P < 0.05). Downregulation of FAM83A led to a reduction in cell proliferation, a decrease in migration ability, and diminished epithelial-mesenchymal transition (EMT) in the lung cancer cell lines. Overexpression of FAM83A was associated with early lymph node metastasis and poor overall survival among LUAD patients. The findings indicated that FAM83A may play a critical role in promoting the LUAD progression and thus might serve as a novel prognostic marker in LUAD.
资助项目	National Natural Science Foundation of China ; Provincial Natural Science Foundation of Anhui ; Fundamental Research Funds for the Central University ; [82000082] ; [2008085QH353] ; [WK9110000124]
WOS关键词	TKI RESISTANCE ; CANCER-CELLS ; OPEN-LABEL ; CHEMOTHERAPY ; ONCOGENES ; ERLOTINIB
WOS研究方向	Oncology
语种	英语
出版者	HINDAWI LTD
WOS记录号	WOS:000871321200001
资助机构	National Natural Science Foundation of China ; Provincial Natural Science Foundation of Anhui ; Fundamental Research Funds for the Central University
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129446]
专题	中国科学院合肥物质科学研究院
通讯作者	Zhang, Junqiang
作者单位	1.Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Resp & Crit Care Med, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China 2.Bengbu Med Coll, Bengbu 233030, Anhui, Peoples R China 3.Univ Sci & Technol China, Hefei 230026, Peoples R China 4.Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei 230031, Peoples R China
推荐引用方式 GB/T 7714	Liu, Xin,Fu, Meng,Xia, Daqing,et al. Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma[J]. JOURNAL OF ONCOLOGY,2022,2022.
APA	Liu, Xin.,Fu, Meng.,Xia, Daqing.,Ji, Zimei.,Hu, Nana.,...&Zhang, Junqiang.(2022).Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma.JOURNAL OF ONCOLOGY,2022.
MLA	Liu, Xin,et al."Overexpression of FAM83A Is Associated with Poor Prognosis of Lung Adenocarcinoma".JOURNAL OF ONCOLOGY 2022(2022).